However, a first-in-class pan-PPAR agonist (Lanifibranor) targeting all three PPAR isoforms showed potential as a NASH treatment in a recent clinical trial39, indicating that the complex etiology of NASH necessitates targeting multiple pathways for successful outcome. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.